[Immunotherapy of solid tumors. Current status and prospects]. 1996

M G Valente, and F Tagliaferri, and F Stipa, and K Arklins, and S Cesareo, and I Sirovich

Immunotherapy is the most recent therapeutic strategy in the treatment of cancer. It has not yet achieved an elevated curative efficiency and a wide clinical application. Nevertheless the possibilities of improvement seem very promising. The knowledge of the immune response mechanisms and the first clinical trials have determined a more efficient immunotherapy. Here we will critically analyze current immunotherapeutic strategies by reviewing the latest and the most important experimental works. The latest protocols of immunotherapy have been aimed to be more integrated in the physiological immune response schemes. The orientation of the experimental works have been changed from non specific immunotherapy using lymphokines to immunotherapy with specific lymphocytes expanded in vitro and, finally, the active specific immunotherapy in vivo by modificated tumoral vaccines or by variously manipulated tumoral antigens.

UI MeSH Term Description Entries
D007167 Immunotherapy Manipulation of the host's immune system in treatment of disease. It includes both active and passive immunization as well as immunosuppressive therapy to prevent graft rejection. Immunotherapies
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia

Related Publications

M G Valente, and F Tagliaferri, and F Stipa, and K Arklins, and S Cesareo, and I Sirovich
January 2019, Mass spectrometry reviews,
M G Valente, and F Tagliaferri, and F Stipa, and K Arklins, and S Cesareo, and I Sirovich
July 2010, Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences,
M G Valente, and F Tagliaferri, and F Stipa, and K Arklins, and S Cesareo, and I Sirovich
May 2009, Immunotherapy,
M G Valente, and F Tagliaferri, and F Stipa, and K Arklins, and S Cesareo, and I Sirovich
July 1979, Minnesota medicine,
M G Valente, and F Tagliaferri, and F Stipa, and K Arklins, and S Cesareo, and I Sirovich
October 1996, Immunology and cell biology,
M G Valente, and F Tagliaferri, and F Stipa, and K Arklins, and S Cesareo, and I Sirovich
October 2009, Current opinion in pharmacology,
M G Valente, and F Tagliaferri, and F Stipa, and K Arklins, and S Cesareo, and I Sirovich
May 2021, Journal of personalized medicine,
M G Valente, and F Tagliaferri, and F Stipa, and K Arklins, and S Cesareo, and I Sirovich
January 2022, Medicinal research reviews,
M G Valente, and F Tagliaferri, and F Stipa, and K Arklins, and S Cesareo, and I Sirovich
March 2009, Journal of biomedical science,
M G Valente, and F Tagliaferri, and F Stipa, and K Arklins, and S Cesareo, and I Sirovich
January 2021, Frontiers in immunology,
Copied contents to your clipboard!